MedTrace Logo

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

NCT05602090 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-04-28

No results posted yet for this study

Summary

Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients

Conditions

  • Poor Ovarian Reserve

Interventions

DRUG

4 IU of recombinant GH (Somatotropin )

4 IU of recombinant GH

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Beni-Suef University · Faculty of Medicine Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-09-04
Completion
2023-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05602090 on ClinicalTrials.gov